



GENETICS & WOMEN'S HEALTH

# BRCAssure<sup>®</sup> *BRCA1* and *BRCA2* analysis


Because knowledge is a powerful tool




# Hereditary breast and ovarian cancer

**Patients with *BRCA* mutations are at increased risk for breast, ovarian and other cancers.**


- Mutations in *BRCA1* and *BRCA2* account for the vast majority of families with hereditary breast and ovarian cancer syndrome (HBOC).<sup>1</sup>
- The estimated lifetime risk of breast cancer in women with *BRCA1* mutations is 55%-72% by age 70; for *BRCA2*, the risk is 45%-69%.<sup>2</sup>
- The risk of ovarian cancer is 39%-44% for a woman with *BRCA1* and 11%-17% with *BRCA2*.<sup>2</sup>
- Both men and women with mutations in *BRCA1/2* may also be at increased risk of other cancers, including pancreatic, prostate and melanoma.<sup>2</sup>




Approximately 1 in 40 Ashkenazi Jewish individuals carries one of three founder mutations.<sup>2</sup>



The overall prevalence of *BRCA1* and *BRCA2* mutations in the general population is estimated at 1 in 400<sup>2</sup> and varies with ethnicity.





Knowing your patient's *BRCA* mutation status may assist in developing tailored prevention and treatment strategies.

## Indications for BRCAssure testing<sup>1,3</sup>

**Consider BRCAssure testing for your patients if their personal or family history has one of the following:**

- Breast cancer diagnosed at age 50 or younger
- Ovarian cancer
- Both breast and ovarian cancer
- Multiple primary breast cancers
- Male breast cancer
- Triple-negative breast cancer
- Pancreatic cancer
- Metastatic prostate cancer
- A previously identified *BRCA1* or *BRCA2* mutation in the family
- Ashkenazi Jewish ancestry
- Three or more relatives with breast cancer at any age

Notes: "Breast cancer" includes both invasive and ductal carcinoma in situ (DCIS). "Ovarian cancer" includes epithelial ovarian cancer, fallopian tube and primary peritoneal cancer.<sup>3</sup> Complete Guidelines may be found at [www.nccn.org](http://www.nccn.org); [www.ACOG.org](http://www.ACOG.org).

NCCN® is a trademark owned by the National Comprehensive Cancer Network, Inc.


---

### Genetic counseling is highly recommended when *BRCA* testing is offered and after results are provided<sup>1</sup>

Labcorp provides nationwide access to genetic counseling expertise through our telegenetic counseling program and provides convenience to patients with online scheduling. Your patients can quickly schedule an appointment at [womenshealth.labcorp.com/genetic-counseling](http://womenshealth.labcorp.com/genetic-counseling).

Call **855-GC-CALLS (855-422-2557)** to learn more about our exceptional services or visit [womenshealth.labcorp.com/genetic-counseling](http://womenshealth.labcorp.com/genetic-counseling).

Test/Panel Name	Test No.
BRCAssure: Comprehensive <i>BRCA1/2</i> Analysis	<b>485030</b>
BRCAssure: Ashkenazi Jewish Panel	<b>485097</b>
BRCAssure: <i>BRCA1</i> Targeted Analysis	<b>485066</b>
BRCAssure: <i>BRCA2</i> Targeted Analysis	<b>485081</b>



Specimen requirements:  
7 mL whole blood lavender-top (EDTA) tube  
**OR**  
2 mL saliva Oragene®•Dx saliva collection kit

## A continuity of care, pioneering science, professional service

We provide the scientific expertise you need and the customer experience patients want.

### Rapid results

Samples have a typical turnaround time of 3 weeks after a test arrives at our lab.

### Extensive managed care contracts

Help patients maximize their benefits. Where applicable, Labcorp can initiate prior authorization for hereditary cancer testing with or without a specimen.

### Convenient blood draws

We have a nationwide network of patient service centers, allowing for convenient access to sample collection. Visit [labcorp.com](http://labcorp.com) to find your nearest location.

### Confirmatory testing for direct-to-consumer results

Our hereditary cancer portfolio provides the testing options needed to confirm patient results from direct-to-consumer genetics laboratories as appropriate.

### Women's health and wellness

Labcorp provides access to a complete women's health offering featuring a full range of testing and services that support the continuity of care for your patients through a single laboratory.

### References

1. American College of Obstetricians and Gynecologists. Hereditary Breast and Ovarian Cancer Syndrome. ACOG Practice Bulletin. No. 182. *Obstet Gynecol.* 2017; Sep;130(3):e-110-e126.
2. Petrucelli, N et al. *BRCA1* and *BRCA2* Hereditary Breast and Ovarian Cancer. Gene Reviews. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK1247>. Accessed November 9, 2022.
3. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. NCCN Guidelines Version 1.2023. Available at: [http://www.nccn.org/professionals/physician\\_gls/pdf/genetics\\_screening.pdf](http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf). Accessed October 4, 2022.

### Call Us

Toll-free (within the US) at 800.848.4436

### Follow Us



### Visit Us

[womenshealth.labcorp.com](http://womenshealth.labcorp.com)

Labcorp  
3400 Computer Drive  
Westborough, Massachusetts 01581

